{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964008,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00296-021-04926-z","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T01:02:32Z","timestamp":1625533352000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6197-5659","authenticated-orcid":false,"given":"Aysa","family":"Hacioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-1312","authenticated-orcid":false,"given":"Sermin","family":"Borekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-8368","authenticated-orcid":false,"given":"Melike","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-4715","authenticated-orcid":false,"given":"Yesim","family":"Ozguler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-7305","authenticated-orcid":false,"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-2282","authenticated-orcid":false,"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-2918","authenticated-orcid":false,"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-9690","authenticated-orcid":false,"given":"Izzet","family":"Fresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1652","authenticated-orcid":false,"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-8258","authenticated-orcid":false,"given":"Huri","family":"Ozdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9309-0740","authenticated-orcid":false,"given":"Sebahattin","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-9253","authenticated-orcid":false,"given":"Ibrahim","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9229","authenticated-orcid":false,"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3886-2138","authenticated-orcid":false,"given":"H. Gul","family":"Ongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"6","key":"4926_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","volume":"44","author":"J Keane","year":"2005","unstructured":"Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44(6):714\u2013720. https:\/\/doi.org\/10.1093\/rheumatology\/keh567","journal-title":"Rheumatology"},{"issue":"15","key":"4926_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098\u20131104. https:\/\/doi.org\/10.1056\/NEJMoa011110","journal-title":"N Engl J Med"},{"issue":"9","key":"4926_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261\u20131265. https:\/\/doi.org\/10.1086\/383317","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4926_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/424455","volume":"39","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39(8):1254\u20131255. https:\/\/doi.org\/10.1086\/424455","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4926_CR5","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766\u20131772. https:\/\/doi.org\/10.1002\/art.21043","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4926_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group B (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122\u20132127. https:\/\/doi.org\/10.1002\/art.11137","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4926_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/ard.62.8.791","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62(8):791. https:\/\/doi.org\/10.1136\/ard.62.8.791","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4926_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care C","year":"2005","unstructured":"British Thoracic Society Standards of Care C (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60(10):800\u2013805. https:\/\/doi.org\/10.1136\/thx.2005.046797","journal-title":"Thorax"},{"issue":"3","key":"4926_CR9","first-page":"237","volume":"31","author":"JE Fonseca","year":"2006","unstructured":"Fonseca JE, Lucas H, Canhao H, Duarte R, Santos MJ, Villar M et al (2006) Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors. Acta Reumatol Port 31(3):237\u2013245 (Epub 2006\/11\/11 PubMed PMID: 17094335)","journal-title":"Acta Reumatol Port"},{"issue":"4","key":"4926_CR10","first-page":"413","volume":"24","author":"G Valesini","year":"2006","unstructured":"Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24(4):413\u2013423 (Epub 2006\/09\/08 PubMed PMID: 16956432)","journal-title":"Clin Exp Rheumatol"},{"issue":"3 Suppl 66","key":"4926_CR11","first-page":"S28","volume":"29","author":"C Salvarani","year":"2011","unstructured":"Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E et al (2011) Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 29(3 Suppl 66):S28-41 (Epub 2011\/10\/01 PubMed PMID: 21906425)","journal-title":"Clin Exp Rheumatol"},{"issue":"43\u201344","key":"4926_CR12","first-page":"620","volume":"137","author":"C Beglinger","year":"2007","unstructured":"Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM et al (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137(43\u201344):620\u2013622","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"4926_CR13","first-page":"6","volume":"101","author":"PM Kavanagh","year":"2008","unstructured":"Kavanagh PM, Gilmartin JJ, O\u2019Donnell J, O\u2019Flanagan D (2008) Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 101(1):6\u20137 (Epub 2008\/03\/29 PubMed PMID: 18369014)","journal-title":"Ir Med J"},{"issue":"6","key":"4926_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-0029-1214673","volume":"63","author":"R Diel","year":"2009","unstructured":"Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329\u2013334. https:\/\/doi.org\/10.1055\/s-0029-1214673","journal-title":"Pneumologie"},{"issue":"5","key":"4926_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185\u20131206. https:\/\/doi.org\/10.1183\/09031936.00028510","journal-title":"Eur Respir J"},{"issue":"5","key":"4926_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625\u2013639. https:\/\/doi.org\/10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4926_CR17","unstructured":"Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K et al (2012) Guidelines for screening prophylaxis and critical information prior to initiating anti TNF alpha treatment. Dan Med J 59(7):C4480"},{"issue":"8","key":"4926_CR18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3899\/jrheum.120165","volume":"39","author":"C Bombardier","year":"2012","unstructured":"Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 39(8):1583\u20131602. https:\/\/doi.org\/10.3899\/jrheum.120165","journal-title":"J Rheumatol"},{"issue":"7","key":"4926_CR19","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/art.34382","volume":"64","author":"EC Hsia","year":"2012","unstructured":"Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S et al (2012) Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 64(7):2068\u20132077. https:\/\/doi.org\/10.1002\/art.34382","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4926_CR20","first-page":"1271","volume":"35","author":"D Vassilopoulos","year":"2008","unstructured":"Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ (2008) Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 35(7):1271\u20131276 (Epub 2008\/04\/03 PubMed PMID: 18381793)","journal-title":"J Rheumatol"},{"issue":"14","key":"4926_CR21","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","volume":"286","author":"GH Mazurek","year":"2001","unstructured":"Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR et al (2001) Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent mycobacterium tuberculosis infection. JAMA 286(14):1740\u20131747. https:\/\/doi.org\/10.1001\/jama.286.14.1740","journal-title":"JAMA"},{"issue":"5","key":"4926_CR22","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s10067-020-05443-3","volume":"40","author":"E Seyhoglu","year":"2021","unstructured":"Seyhoglu E, Uyaroglu OA, Erden A, Kilic L, Karadag O, Akdogan A et al (2021) QuantiFERON(R)-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guerin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clin Rheumatol 40(5):2027\u20132035. https:\/\/doi.org\/10.1007\/s10067-020-05443-3","journal-title":"Clin Rheumatol"},{"issue":"7","key":"4926_CR23","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s10620-019-5475-3","volume":"64","author":"RF Amorim","year":"2019","unstructured":"Amorim RF, Viegas ERC, Carneiro AJV, Esberard BC, Chinem ES, Correa RS et al (2019) Superiority of interferon gamma assay over tuberculin skin test for latent tuberculosis in inflammatory bowel disease patients in Brazil. Dig Dis Sci 64(7):1916\u20131922. https:\/\/doi.org\/10.1007\/s10620-019-5475-3","journal-title":"Dig Dis Sci"},{"issue":"9","key":"4926_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/thorax.57.9.804","volume":"57","author":"L Wang","year":"2002","unstructured":"Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 57(9):804\u2013809. https:\/\/doi.org\/10.1136\/thorax.57.9.804","journal-title":"Thorax"},{"issue":"32","key":"4926_CR25","first-page":"229","volume":"70","author":"Global tuberculosis programme and global programme on vaccines","year":"1995","unstructured":"Global tuberculosis programme and global programme on vaccines (1995) Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec 70(32):229\u2013231 (Epub 1995\/08\/11 PubMed PMID: 7669527)","journal-title":"Wkly Epidemiol Rec"},{"issue":"7","key":"4926_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/ecco-jcc\/jjx022","volume":"11","author":"C Taxonera","year":"2017","unstructured":"Taxonera C, Ponferrada A, Bermejo F, Riestra S, Saro C, Martin-Arranz MD et al (2017) Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. J Crohns Colitis 11(7):792\u2013800. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx022","journal-title":"J Crohns Colitis"},{"issue":"11","key":"4926_CR27","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjy104","volume":"12","author":"C Taxonera","year":"2018","unstructured":"Taxonera C, Ponferrada A, Riestra S, Bermejo F, Saro C, Martin-Arranz MD et al (2018) Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease. J Crohns Colitis 12(11):1270\u20131279. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy104","journal-title":"J Crohns Colitis"},{"issue":"3","key":"4926_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7326\/0003-4819-84-3-261","volume":"84","author":"M Schatz","year":"1976","unstructured":"Schatz M, Patterson R, Kloner R, Falk J (1976) The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 84(3):261\u2013265. https:\/\/doi.org\/10.7326\/0003-4819-84-3-261","journal-title":"Ann Intern Med"},{"issue":"3","key":"4926_CR29","first-page":"474","volume":"34","author":"G Hatemi","year":"2007","unstructured":"Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H (2007) Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 34(3):474\u2013480 (Epub 2007\/02\/15 PubMed PMID: 17299840)","journal-title":"J Rheumatol"},{"issue":"22","key":"4926_CR30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594\u20131602. https:\/\/doi.org\/10.1056\/NEJM200011303432202","journal-title":"N Engl J Med"},{"key":"4926_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/291031","author":"M Arenas Miras Mdel","year":"2014","unstructured":"Arenas Miras Mdel M, Hidalgo-Tenorio C, Jimenez-Gamiz P, Jimenez-Alonso J (2014) Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. Biomed Res Int. https:\/\/doi.org\/10.1155\/2014\/291031","journal-title":"Biomed Res Int"},{"key":"4926_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/430134","author":"S Agarwal","year":"2014","unstructured":"Agarwal S, Das SK, Agarwal GG, Srivastava R (2014) Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-tnf therapies. Interdiscip Perspect Infect Dis. https:\/\/doi.org\/10.1155\/2014\/430134","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"11","key":"4926_CR33","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/ibd.21605","volume":"17","author":"E Belard","year":"2011","unstructured":"Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK et al (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17(11):2340\u20132349. https:\/\/doi.org\/10.1002\/ibd.21605","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"4926_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3109\/00365521.2015.1064470","volume":"50","author":"GJ Mantzaris","year":"2015","unstructured":"Mantzaris GJ, Tsironikos D, Tzanetakou X, Grispou E, Karatzas P, Kalogeropoulos I et al (2015) The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol 50(12):1451\u20131455. https:\/\/doi.org\/10.3109\/00365521.2015.1064470","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"4926_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2(4):309\u2013313. https:\/\/doi.org\/10.1016\/s1542-3565(04)00060-6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"4926_CR36","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/acr.22063","volume":"65","author":"GS Hazlewood","year":"2013","unstructured":"Hazlewood GS, Naimark D, Gardam M, Bykerk V, Bombardier C (2013) Prophylaxis for latent tuberculosis infection prior to anti-tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. Arthritis Care Res (Hoboken) 65(11):1722\u20131731. https:\/\/doi.org\/10.1002\/acr.22063","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"4926_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0873-2159(15)30022-2","volume":"16","author":"JT Costa","year":"2010","unstructured":"Costa JT, Silva R, Sa R, Cardoso MJ, Ribeiro C, Nienhaus A (2010) Comparison of interferon-gamma release assay and tuberculin test for screening in healthcare workers. Rev Port Pneumol 16(2):211\u2013221 (Epub 2010\/05\/04 PubMed PMID: 20437000)","journal-title":"Rev Port Pneumol"},{"issue":"4","key":"4926_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.201107-1244OC","volume":"185","author":"JD Mancuso","year":"2012","unstructured":"Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L et al (2012) Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 185(4):427\u2013434. https:\/\/doi.org\/10.1164\/rccm.201107-1244OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4926_CR39","unstructured":"Keser GDH, Akkoc N, \u0130nan\u00e7 M, \u00d6zkara \u015e, \u00d6ngen G, G\u00fcl A et al (2005) Romatizma ara\u015ft\u0131rma ve e\u011fitim derne\u011fi uzla\u015f\u0131 toplant\u0131 raporu. \u0130zmir"},{"issue":"8","key":"4926_CR40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174(8):935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4926_CR41","unstructured":"Geiter LJ, Gordin FM, Hershfield E, Horsburgh CR, Jereb JA, Jordan TJ et al (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 49:1\u201351"},{"issue":"11","key":"4926_CR42","first-page":"1192","volume":"10","author":"M Farhat","year":"2006","unstructured":"Farhat M, Greenaway C, Pai M, Menzies D (2006) False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10(11):1192\u20131204 (Epub 2006\/11\/30 PubMed PMID: 17131776)","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"4926_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-009-1027-z","volume":"30","author":"MN Tamborenea","year":"2010","unstructured":"Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A (2010) Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 30(5):613\u2013616. https:\/\/doi.org\/10.1007\/s00296-009-1027-z","journal-title":"Rheumatol Int"},{"issue":"3","key":"4926_CR44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1183\/09031936.00107608","volume":"33","author":"F Bartalesi","year":"2009","unstructured":"Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D et al (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33(3):586\u2013593. https:\/\/doi.org\/10.1183\/09031936.00107608","journal-title":"Eur Respir J"},{"key":"4926_CR45","unstructured":"World Health Organisation (2020) Global tuberculosis report 2020. Geneva. Licence: CC BY-NC-SA 3.0 IGO"},{"key":"4926_CR46","unstructured":"T\u00fcrkiye\u2019de Verem Sava\u015f\u0131 2019 Raporu, 1168. Ankara, 2020"},{"key":"4926_CR47","first-page":"25","volume":"1","author":"ES Cs U\u00e7an","year":"2000","unstructured":"Cs U\u00e7an ES, Abadoglu \u00d6, Arpaz S, Ellidokuz H (2000) T\u00fcberk\u00fclin Testi Sonu\u00e7lar\u0131n\u0131n Yorumlanmas\u0131 \u00dclkemiz Standartlar\u0131 ve Yeni Gereksinimler. Toraks Dergisi 1:25\u201329","journal-title":"Toraks Dergisi"},{"issue":"2","key":"4926_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","volume":"8","author":"A Lalvani","year":"2008","unstructured":"Lalvani A, Millington KA (2008) Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 8(2):147\u2013152. https:\/\/doi.org\/10.1016\/j.autrev.2008.07.011","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4926_CR49","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/ar3882","volume":"14","author":"G Hatemi","year":"2012","unstructured":"Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H (2012) Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 14(3):R147. https:\/\/doi.org\/10.1186\/ar3882","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4926_CR50","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/ard.2002.004598","volume":"62","author":"J Vanhoof","year":"2003","unstructured":"Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P (2003) High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62(12):1241\u20131242. https:\/\/doi.org\/10.1136\/ard.2002.004598","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4926_CR51","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10067-014-2528-z","volume":"33","author":"J Bourre-Tessier","year":"2014","unstructured":"Bourre-Tessier J, Arino-Torregrosa M, Choquette D (2014) Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and\/or biologic agents. Clin Rheumatol 33(8):1049\u20131053. https:\/\/doi.org\/10.1007\/s10067-014-2528-z","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04926-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:07:58Z","timestamp":1657843678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04926-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4926"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04926-z","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Istanbul University-Cerrahpasa Medical Faculty (date: 02.09.2014, approval number: A-30).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the only patient whose medical data is reported in detail.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}